TNFRSF4 and cholangiocarcinoma: Two clinical trials are currently underway targeting CD40 (NCT03329950) and OX40 (NCT03071757) as monotherapy or in combination therapy for advanced cancers including BTC (191), Additionally, investigations are underway into combination strategies involving ICIs alongside other treatments for CCA, in addition to ICI immunotherapy administered alone.